Diabodies Targeting Epithelial Membrane Protein 2 Reduce Tumorigenicity of Human Endometrial Cancer Cell Lines

@article{Shimazaki2008DiabodiesTE,
  title={Diabodies Targeting Epithelial Membrane Protein 2 Reduce Tumorigenicity of Human Endometrial Cancer Cell Lines},
  author={K. Shimazaki and E. J. Lepin and B. Wei and A. Nagy and Catherine P Coulam and Sergey Mareninov and M. Fu and A. Wu and J. Marks and J. Braun and L. Gordon and M. Wadehra},
  journal={Clinical Cancer Research},
  year={2008},
  volume={14},
  pages={7367 - 7377}
}
  • K. Shimazaki, E. J. Lepin, +9 authors M. Wadehra
  • Published 2008
  • Biology, Medicine
  • Clinical Cancer Research
    • Purpose: Endometrial cancer is the most common gynecologic malignancy. One promising biomarker is epithelial membrane protein 2 (EMP2), and its expression is an independent prognostic indicator for tumors with poor clinical outcome expression. The present study assesses the suitability of EMP2 as a therapeutic target. Experimental Design: Human monovalent anti-EMP2 antibody fragments were isolated from a human phage display library and engineered as bivalent antibody fragments (diabodies) with… CONTINUE READING
    View on AACR
    clincancerres.aacrjournals.org
    24 Citations
    Background Citations
    12
    Methods Citations
    7
    24 Citations
    Citation Type

    Citation Type

    Epithelial Membrane Protein-2 Is a Novel Therapeutic Target in Ovarian Cancer
    • 26
    • PDF
    Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
    • 25
    • PDF
    Large Molecule Therapeutics Rationale and Preclinical Ef fi cacy of a Novel Anti-EMP 2 Antibody for the Treatment of Invasive Breast Cancer
    • PDF
    EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF
    • 34
    Epithelial Membrane Protein-2 (EMP2) Activates Src Protein and Is a Novel Therapeutic Target for Glioblastoma*
    • 21
    • PDF
    Positron Emission Tomography Imaging of Endometrial Cancer Using Engineered Anti-EMP2 Antibody Fragments
    • 15
    • PDF
    EMP1, EMP 2, and EMP3 as novel therapeutic targets in human cancer.
    • 24
    Epithelial membrane protein 2: Molecular interactions and clinical implications
    • 7
    The Pivotal Roles of the Epithelial Membrane Protein Family in Cancer Invasiveness and Metastasis
    • 4
    • PDF
    Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells.
    • 9

    References

    SHOWING 1-10 OF 64 REFERENCES
    Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity.
    • 46
    • PDF
    Steroid hormone regulation of EMP2 expression and localization in the endometrium
    • 26
    Treatment of Human B Cell Lymphoma Xenografts with a CD3 × CD19 Diabody and T Cells1
    • 84
    • PDF
    Inhibition of Endometrial Cancer Cell Lines by Mifepristone (RU 486)
    • 41
    Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.
    • 216
    • PDF
    The tetraspan protein EMP2 increases surface expression of class I major histocompatibility complex proteins and susceptibility to CTL-mediated cell death.
    • 37
    Expression of epithelial membrane protein‐2 is associated with endometrial adenocarcinoma of unfavorable outcome
    • 43
    Knockdown of the tetraspan protein epithelial membrane protein-2 inhibits implantation in the mouse.
    • 37
    • PDF
    Epithelial membrane protein-2 regulates surface expression of αvβ3 integrin in the endometrium
    • 46
    • PDF
    Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    • 128
    • PDF